The present study was undertaken to investigate the mechanism by which 1 ␣ , 25-dihydroxy-cholecalciferol [1 ␣ ,25-(OH) 2 -VD 3 ] modulates the differentiation of mouse 3T3-L1 preadipocytes into mature adipocytes. Treatment with 1 ␣ ,25-(OH) 2 -VD 3 in the presence of insulin, dexamethasone and 3-isobutyl-1-methyl-xanthine significantly inhibited the triacylglycerol accumulation, and mRNA expressions of adipocytokines (adiponectin and tumor necrosis factor-␣ ) and plasminogen activator inhibitor-1 in the piconanomolar concentration range, indicating that 1 ␣ ,25-(OH) 2 -VD 3 under physiological conditions inhibits the differentiation of 3T3-L1 cells. 1 ␣ ,25-(OH) 2 -VD 3 potently reduced the mRNA and/or protein expressions of CCAAT-enhancer binding protein ␣ (C/EBP ␣ ) and peroxisome proliferator-activated receptor ␥ (PPAR ␥ ), and the nuclear translocation of PPAR ␥ . Furthermore, it inhibited the mRNA expression and phosphorylation of extracellular signalregulated kinase (ERK), one of mitogen-activated protein kinases. These results indicate that 1 ␣ ,25-(OH) 2 -VD 3 can be an inhibitor of adipocyte differentiation, and suggest, in addition to C/EBP ␣ and PPAR ␥ , an important role of ERK in mediating 1 ␣ ,25-(OH) 2 -VD 3 -induced alteration in adipocyte differentiation.
Obesity is an important disease in the realm of preventive medicine because it is regarded as a risk factor for a broad spectrum of cardiometabolic disturbances, including dyslipidemia, hypertension, glucose intolerance, cardiovascular disease and type 2 diabetes mellitus ( 1 , 2 ) .
Adipocyte precursor cells (i.e., preadipocytes) are present throughout life. Accordingly, obesity may be partially mediated by stimulating the differentiation of preadipocytes into adipocytes or by increasing fat accumulation in the differentiated adipocytes ( 3 ). Furthermore, adipose tissue has recently been identified as an endocrine organ that secretes various kinds of bioactive molecules called adipocytokines ( 4 , 5 ) . The differentiation of preadipocytes into adipocytes is accompanied by many changes in gene expression, e.g., a dramatic increase in the expression of CCAAT/enhancer binding protein ␣ (C/EBP ␣ ) and peroxisome proliferator-activated receptor ␥ (PPAR ␥ ) ( 6 , 7 ) . Recently, it has been suggested that the mitogen-activated protein kinase (MAPK) signaling pathway regulates the expression of C/EBP ␣ and PPAR ␥ mRNA during adipogenesis (8) (9) (10) . Murine 3T3-L1 preadipocytes have been frequently used to study the differentiation of preadipocytes into mature adipocytes in vitro (11) (12) (13) .
There is a substantial body of circumstantial evidence that excess body fat is associated with an increased risk of suboptimal vitamin D status (14) (15) (16) . 1 ␣ ,25-Dihydroxy-cholecalciferol [1 ␣ ,25-(OH) 2 -VD 3 ], the most active form of vitamin D 3 metabolite, has previously been shown to regulate adipocyte differentiation. In early reports, a vitamin D receptor (VDR)-like molecule was detected in 3T3-L1 cells ( 17 ) , and 1 ␣ ,25-(OH) 2 -VD 3 was shown to pose an inhibitory effect on 3T3-L1 differentiation on the basis of its inhibition of glycerophosphate dehydrogenase activity and triacylglycerol (TG) content ( 17 , 18 ) or its ability to counter the stimulatory effect of the PPAR ␥ ligand on 3T3-L1 differentiation ( 19 ) . 1 ␣ ,25-(OH) 2 -VD 3 was also able to inhibit adipocyte differentiation in mouse bone marrow stromal cells ( 20 ) .
In the present study, we aimed to clarify the requirement of the MAPK signaling pathway for 1 ␣ ,25-(OH) 2 -VD 3 -induced modulation of adipocyte differentiation, using 3T3-L1 cells. Adipocyte differentiation . 3T3-L1 preadipocytes were cultured at 37˚C in a humidified atmosphere of 5% CO 2 /95% air. The cells were maintained in growth medium (DMEM with 10% FBS and 1% penicillin-streptomycin). Differentiation was induced according to the protocol enclosed with the 3T3-L1 preadipocytes from the European Collection of Cell Cultures: differentiation of the cells was initiated 2 d after confluence for 3 d in a growth medium containing 1 g/mL insulin, 0.25 M dexamethasone and 0.5 m M IBMX. This was followed by 2 d in a growth medium containing 1 g/mL insulin. Thereafter, the cells were cultured in the growth medium for 2 d.
MATERIALS AND METHODS

Materials
Treatment with 1 ␣ ,25-(OH) 2 -VD 3 . 1 ␣ ,25-(OH) 2 -VD 3 was prepared in Me 2 SO and added to the medium from day 3 (time of addition of insulin, dexamethasone and IBMX). The Me 2 SO concentration was maintained at 0.25% of the total volume, and preliminary experiments demonstrated no significant effects of 0.25% Me 2 SO on cell differentiation.
Measurement of TG . The TG contents in the cells were measured as described previously by us ( 21 ) . The amount of TG, an index of lipid accumulation, was quantitatively measured using a Triglyceride E-test Wako kit following normalization by protein amounts and expressed as TG contents ( g/mg protein).
Measurement of PPAR ␥ , and phosphorylated (p-) MAPK protein expressions . Untreated or 1 ␣ ,25-(OH) 2 -VD 3 -treated 3T3-L1 cells up to day 5 were washed with icecold PBS, and then lysed. The prepared lysates were mixed with an equal volume of solubilization buffer [20% glycerol, 4% SDS, 2% 2-mercaptoethanol, 125 m M Tris/HCl (pH 6.8)] and boiled for 10 min. Cell lysates were analyzed using a 7.5% polyacrylamide gel. Proteins were transferred to nitrocellulose membranes by electroblotting and the membranes were incubated overnight in TBS-T (0.14 M NaCl, 20 m M Tris and 0.1% Tween 20, pH 7.4) containing the respective primary antibody (PPAR ␥ , p-p38MAPK, p-ERK or p-JNK antibody) and 3% nonfat dry milk. After incubation, the membranes were incubated with secondary goat HRPlinked anti-rabbit IgG antibody for 1 h, followed by ECL (Amersham-Pharmacia Corp., Buckingham, UK).
Measurement of nuclear bioactive PPAR ␥ . Bioactive PPAR ␥ in nuclear extract of 3T3-L1 cells was determined as described in our previous paper (21) . Briefly, the nuclear fractions from 3T3-L1 cells were separated using the Nuclear Extraction kit (Marligen Biosciences Inc., Rockville, MD, USA). Bioactive PPAR␥ in the nucleus was measured using the PPAR␥ Transcription Factor Assay kit.
Measurement of mRNA expressions. Untreated or 1␣,25-(OH)2-VD3-treated 3T3-L1 cells up to day 5 were washed with ice-cold PBS. Total cellular RNA was prepared using TRIzol reagent. One microgram of total RNA was reverse transcribed into cDNA using a Transcriptor First Strand cDNA Synthesis kit. The concentration and quality of the purified total RNA were determined spectrophotometrically at 260 nm and by the OD260:280 ratio. mRNA expression was measured by a real time RT-PCR using a LightCycler FirstStart DNA Master plus SYBR green reagent and LightCycler instrument (Roche). Results were expressed as relative amount of the target mRNA to ␤-action mRNA, and the values in the presence or absence of drugs were expressed as relative amount to the None value (no addition of insulin, dexamethasone or IBMX).
The primers for ␤-actin, adiponectin, TNF-␣, PAI-1, PPAR␥, C/EBP␣, p38MAPK␣, p38MAPK␤, ERK1/2 and JNK were as follows: ␤-actin, 5′-ACACCCCAGCCATG-TACG-3′, 5′-TGGTGGTGAAGCTGTAGCC-3′; adiponectin, 5′-GGCAGGCATCCCAGGACATC-3′, 5′-TCTCACCC-TTAGGACCAAGAAGAC-3′; TNF-␣, 5′-ACCTTTCCAGA-TTCTTCCCTGAG-3′, 5′-CCCGGCCTTCCAAATAAATAC-ATT-3′; PAI-1, 5′-CCTCTTCATGGGCCAAGT-3′, 5′-GG-TAAGGAGGAGTTGCCTTC-3′; PPAR␥, 5′-GTGAAGCC-CATCGAGGACA-3′, 5′-TGGAGCACCTTGGCGAACA-3′; C/EBP␣, 5′-ATGGTTTCGGGTCGCTGGAT-3′, 5′-CCACG-GCCTGACTCCCTCAT-3′; p38MAPK␣, 5′-CCTTGACC-AAGAAGAAATG-3′, 5′-ACAGACGAACAGACAGACAC-3′; p38MAPK␤, 5′-ACCAAGAAGTCCTTAGCTTC-3′, 5′-GTAGAGTTTCTCAAGGCAAG-3′; ERK1/2, 5′-GCTCAC-CCTTACCTGGAACA-3′, 5′-GGACCAGATCCAAAAGGA-CA-3′; JNK, 5′-AATGGTTTGCCACAAAATCC-3′, 5′-GAGTCAGCTGGGAAAAGCAC-3′. Statistical analysis. Results are the meansϮSE. The significance of differences between two groups was assessed using the t-test, and differences between multiple groups were assessed by one-way analysis of variance (ANOVA) followed by Scheffe's multiple range test. p-values less than 0.05 were considered significant. Figure 1 shows the effect of 1␣,25-(OH) 2-VD3 on the TG contents, a marker of lipid accumulation, in 3T3-L1 cells. An incubation of 3T3-L1 preadipocytes with insulin, dexamethasone and IBMX (Cont.) increased the TG contents by 4-5 fold compared to the None value (no addition of insulin, dexamethasone or IBMX) (data not shown). At concentrations ranging from 0.1 to 100 nM, 1␣,25-(OH)2-VD3 dose-dependently inhibited the TG contents. The reduction of TG accumulation was appar- TG contents in 3T3-L1 cells. At a concentration of 10 nM, VD3, 25-OH-VD3 and 1␣-OH-VD3 showed no significant effect on the TG accumulation, whereas 1␣,25-(OH)2-VD3 inhibited it by 88%. Although 1␣-OH-VD3 at a concentration of 100 nM reduced the TG accumulation (56% inhibition), the inhibitory effect was weaker than that of 1␣,25-(OH)2-VD3 (92% inhibition). VD3 is produced in the skin in response to ultraviolet B radiation and then converted in the liver to 25-OH-VD3, which acts as a precursor for the renal production of 1␣,25-(OH)2-VD3. Therefore, the results of Fig. 2 indicate that, of the two hydroxyl groups, the 1-hydroxyl position is important for the 1␣,25-(OH)2-VD3 effect, and that only 1␣,25-(OH)2-VD3 formed naturally in the cell body, but not an intermediate, can down-regulate the TG accumulation. Figure 3 illustrates the effects of VD3 and 1␣,25-(OH)2-VD3 on the mRNA expressions of adiponectin, TNF-␣ and PAI-1. After incubation with insulin, dexamethasone and IBMX, 3T3-L1 adipocytes produced more mRNA expressions of adiponectin, TNF-␣ and PAI-1. VD3 at concentrations of 0.5 and 1.0 nM had no significant effect on these three mRNA expression levels, but 1␣,25-(OH)2-VD3 at 0.5 and/or 1.0 nM inhibited all of them (adiponectin mRNA, 94 and 96% inhibition; TNF-␣ mRNA, 8 and 41% inhibition; PAI-1 mRNA, 69 and 86% inhibition). Adipose tissue has been identified as an endocrine organ that secretes various kinds of bioactive molecules called adipocytokines (4, 5) . After differentiation, mature 3T3-L1 adipocytes secrete adiponectin and TNF-␣ (6, 7) . On the other hand, PAI-1 is an important component of the plasminogen/plasmin system as it is the main inhibitor of tissue-type and urokinase-type plasminogen activator. Its plasma level is strongly correlated with parameters that define insulin resistance syndrome, in particular the Body Mass Index and visceral accumulation of body fat, suggesting that PAI-1 may be an adipose tissue-derived circulating peptide (24) . PAI-1 has been reported to be produced in 3T3-L1 cells after differentiation (25) . Thus, the results of Fig. 3 demonstrate that 1␣,25-(OH)2-VD3 under physiological conditions inhibits the differentiation of 3T3-L1 preadipocytes into mature adipocytes.
RESULTS
In an attempt to clarify the mechanism by which 1␣,25-(OH)2-VD3 inhibits the adipocyte differentiation, we measured the mRNA and/or protein expressions of transcriptional regulators involved in adipocyte differentiation (Figs. 4-7) . Figures 4 and 5 illustrate the effects of VD3 and 1␣,25-(OH)2-VD3 on the mRNA and/ or protein expressions of PPAR␥ and C/EBP-␣. As shown in Fig. 4 , the addition of insulin, dexamethasone and IBMX increased PPAR␥ and C/EBP-␣ mRNA levels. VD3 at 0.5 and 1.0 nM had no significant effect on PPAR␥ or C/EBP-␣ mRNA levels, whereas 1␣,25-(OH)2-VD3 at the same concentrations inhibited these two mRNA levels by 89 and 95% for PPAR␥, and 79 and 85% for C/EBP␣. Also, as depicted in Fig. 5 , the addition of insulin, dexamethasone and IBMX significantly enhanced the PPAR␥ in cell lysates and the bioactive PPAR␥ in the nucleus of 3T3-L1 cells. The co-addition of 1␣,25-(OH)2-VD3 (1 nM), but not VD3 (1 nM), with insulin, dexamethasone and IBMX decreased them by 86 and 89%, respectively. These results show that 1␣,25-(OH)2-VD3 inhibits adipocyte differentiation via the C/EBP-␣ and PPAR␥ pathway. This is in accordance with previous findings reported by Blumberg et al. (26) .
Furthermore, Figs. 6 and 7 show the relationship between the MAPK pathway and 1␣,25-(OH)2-VD3-induced inhibition of adipocyte differentiation. As shown in Fig. 6 , after incubation with insulin, dexamethasone and IBMX, 3T3-L1 adipocytes produced more mRNA expressions of p38MAPK␣, p38MAPK␤, ERK1/2 and JNK. The increases in mRNA levels of p38MAPK␣, p38MAPK␤ and ERK1/2 were inhibited by the addition of 1␣,25-(OH)2-VD3 (0.5 and 1.0 nM: p38MAPK␣, 52 and 57% inhibition; p38MAPK␤, 36 and 48% inhibition; ERK1/2, 43 and 51% inhibition) but not VD3. In contrast, neither VD3 nor 1␣,25-(OH)2-VD3 had a significant effect on the increase in JNK mRNA level induced by insulin, dexamethasone or IBMX. 1␣,25-(OH)2-VD3 at 0.5 and 1.0 nM also decreased p-ERK protein expression level, whereas there was no reduction in the protein expression levels of p-p38MAPK and p-JNK (Fig. 7) . The results of Figs. 6 and 7 indicate that the decreases in mRNA level and phosphorylation of ERK are closely related to the 1␣,25-(OH) 2-VD3-induced inhibition of adipocyte differentiation.
DISCUSSION
There are some reports concerning the modulatory role of 1␣,25-(OH)2-VD3 on adipocyte differentiation (14) (15) (16) (17) (18) (19) (20) . However, the molecular mechanism of 1␣,25-(OH)2-VD3-induced modulation remains unclear. The differentiation of preadipocytes into mature insulinresponsive adipocytes involves exposure of a confluent, quiescent population of cells to a variety of effectors that activate a cascade of transcription factors commencing with C/EBP-␤ and C/EBP-␦, which ultimately induce the expression of C/EBP-␣ and PPAR␥ (6, 7) . Although, several laboratories have investigated the role of ERK1/2 MAPK in regulating adipogenesis, their conclusions are somewhat controversial. Some studies claim that activation of ERK1/2 MAPK by various effectors blocks adipogenesis (27, 28) , whereas others suggest that it promotes preadipocyte differentiation (8, 9) . The distinguishing factor might involve the precise timing of MAPK activation during the initial stages of the differentiation process. For instance, effectors that activate the ERK1/2 pathway at late stages of adipogenesis are likely to block adipogenic gene expression due to a MAPK-dependent phosphorylation of PPAR␥ (29, 30) . Activation of the pathway early in adipogenesis prior to PPAR␥ expression might, on the other hand, promote differentiation by activating transcription factors operating to initiate C/EBP-␣ and PPAR␥ expression (10) .
In the present study, 1␣,25-(OH)2-VD3 potently reduced the mRNA and/or protein expressions of C/ EBP␣ and PPAR␥, and the nuclear translocation of PPAR␥. Furthermore, it inhibited the mRNA expression and phosphorylation of ERK, one of the MAPKs. These results suggest a possible role of ERK in mediating 1␣,25-(OH)2-VD3-induced alteration in adipocyte differentiation.
Sato and Hiragun (17) have reported that 1␣,25- (OH)2-VD3 inhibited morphologic and enzymatic expression during differentiation of 3T3-L1 preadipocytes to mature adipocytes, and that the action of 1␣,25-(OH)2-VD3 on the adipocyte differentiation may result from a receptor-mediated event. Blumberg et al. (26) have shown that in the presence of 1␣,25-(OH)2-VD3, VDR blocks adipogenesis of 3T3-L1 cells by downregulating the C/EBP-␣-PPAR␥ pathway. Thus, it appears that the potent reduction of adipocyte differentiation induced by 1␣,25-(OH)2-VD3 shown in the present study is mediated by the VDR. Previously, ERK has been reported to regulate the action of C/EBP-␣ and/or PPAR␥ through a direct (29, 30) or indirect (10) mechanism. However, in the present study, it is unclear whether the 1␣,25-(OH)2-VD3-induced inhibition of adipocyte differentiation can be ascribed to a depression on the ERK effect. Further studies are needed to clarify this problem.
The present findings may provide new information to extend the ongoing debate as to the mechanisms through which 1␣,25-(OH)2-VD3 plays functional roles both physiologically and pharmacologically in animal and human bodies.
